• Bobcat339 Workflows for DNA Methylation Studies

  2026-09-04

  Bobcat339 provides a focused pharmacological route to probe TET1/TET2-dependent DNA demethylation in mesenchymal stem-cell and osteogenesis models. This workflow guide connects dose design, methylation readouts, super-enhancer profiling, and troubleshooting to the UHRF1–5-mC–TGM2 axis reported in senile osteoporosis research.

• Deferasirox Fe3+ chelate in Iron-Stress Assays

  2026-09-04

  Deferasirox Fe3+ chelate provides a defined ferric-iron chemistry tool for studying nutrient stress, lysosomal injury, and iron-handling phenotypes. This workflow combines the compound with the TCF25–V-ATPase pathway identified in a recent CRISPR study, while clearly separating exploratory cell assays from clinical iron chelation.

• Ceapin-A7 Workflow for ATF6α ER Stress Studies

  2026-09-03

  Use Ceapin-A7 as a pathway-focused chemical probe to separate ATF6α signaling from broader unfolded protein response effects. This workflow connects dose planning, orthogonal readouts, and troubleshooting with the PTX3–TLR4/NF-κB/FGF21 findings reported in a recent osteonecrosis study.

• Deferasirox Review: Iron Chelation Evidence

  2026-09-03

  This formulary review positioned deferasirox as an oral, tridentate Fe3+-selective chelator that could address the adherence burden of parenteral deferoxamine in transfusional iron overload. Its most meaningful clinical evidence was noninferiority in patients with higher hepatic iron burdens, alongside strong patient preference for the oral regimen.

• SW033291: A Translational Blueprint for 15-PGDH

  2026-09-02

  SW033291 offers a mechanistically defined way to study 15-PGDH inhibition, prostaglandin E2 elevation, hematopoiesis stimulation, and tissue repair. This thought-leadership perspective connects enzyme kinetics with muscle regeneration findings while separating target-level evidence from compound-specific validation.

• Curcumol, Methionine Metabolism, and HSC Death

  2026-09-02

  A 2026 study links curcumol-induced death of hepatic stellate cells to disruption of methionine metabolism and ATG7-dependent autophagy. Its SAM rescue experiments suggest that methionine-cycle activity is functionally connected to the antifibrotic phenotype, while also defining important limits for interpretation and follow-up studies.

• SkQ1, Mitochondrial Apoptosis, and Muscle Atrophy

  2026-09-01

  This preprint uses a metastatic ovarian cancer mouse model and chronic SkQ1 treatment to test whether mitochondrial reactive oxygen species, apoptosis, or necroptosis drive skeletal muscle atrophy. SkQ1 reduced mitochondrial H2O2 emission and caspase-9/-3 activity in late-stage disease, but muscle fibre loss persisted, separating mitochondrial apoptotic signaling from the maintenance of gastrocnemius atrophy.

• Carbapenemase Transmission in CREC: Guangdong Study

  2026-09-01

  Chen et al. combined carbapenemase-gene localization, conjugation testing, mobile-element profiling, antimicrobial susceptibility testing, and ERIC-PCR to examine carbapenem-resistant Enterobacter cloacae across teaching hospitals in Guangdong. The findings identify plasmid-associated blaNDM-1 and highly transferable resistance determinants as important targets for surveillance, while also showing why genotypic, phenotypic, and epidemiologic data should be interpreted together.

• Atorvastatin and Ferroptosis in Hepatocellular Carcinoma

  2026-08-31

  This 2025 study combines a ferroptosis-related prognostic signature with Connectivity Map drug screening to identify Atorvastatin as a candidate intervention for hepatocellular carcinoma. Computational results and in vitro and in vivo experiments support an association between Atorvastatin exposure, ferroptosis-related responses, and reduced HCC growth and migration, while further validation is needed before clinical translation.

• Ferroptosis Signature Identifies Atorvastatin in HCC

  2026-08-31

  Wang and colleagues developed a four-gene ferroptosis-related prognostic signature for hepatocellular carcinoma and used Connectivity Map analysis to identify Atorvastatin as a candidate treatment. In vitro and in vivo experiments linked Atorvastatin exposure with ferroptosis-like tumor suppression, reduced HCC cell migration, and impaired tumor growth, while also highlighting the need for further mechanistic and clinical validation.

• Ferroptosis Signature and Atorvastatin in HCC

  2026-08-30

  The reference study combines a four-gene ferroptosis-related prognostic signature with Connectivity Map screening to identify Atorvastatin as a candidate agent for hepatocellular carcinoma. Computational prioritization followed by in vitro and in vivo validation linked Atorvastatin treatment with ferroptosis, reduced tumor-cell growth, and impaired migration, while leaving clinical efficacy and the precise molecular mechanism for future study.

• 15-PGDH Inhibition Supports Muscle Repair During Weight Loss

  2026-08-29

  A 2026 PNAS study identifies 15-PGDH inhibition as a strategy for improving skeletal muscle regeneration during semaglutide-associated weight loss. In obese mice, combined treatment preserved weight-loss efficacy while improving regenerative myofiber growth, muscle quality, and recovery of force after injury.

• CCG-1423 RhoA Inhibitor: Workflow Guide

  2026-08-28

  CCG-1423 is a pathway-focused RhoA inhibitor for separating MRTF-A nuclear signaling from broader cytoskeletal responses. This guide translates its mechanism into practical cancer research, apoptosis, invasion, barrier, and exploratory viral-entry workflows while emphasizing controls and interpretation limits.

• Protein A/G Magnetic Co-IP/IP Kit for BATF2 Studies

  2026-08-28

  A practical workflow for testing BATF2–ATF3 relationships, ubiquitin-linked stability, and protein-complex composition in intervertebral disc degeneration models. The Protein A/G Magnetic Co-IP/IP Kit combines Fc-selective capture, rapid magnetic handling, and SDS-PAGE- or mass spectrometry-ready elution for reproducible interaction studies.

• Dicoumarol Targets IRE1α in ER Stress Liver Injury

  2026-08-27

  Yang and colleagues developed a screening workflow that combines kinase-domain molecular docking with an XBP1s reporter assay to identify dicoumarol as an inhibitor of IRE1α activation. The compound reduced tunicamycin- and carbon tetrachloride-associated endoplasmic reticulum stress and protected mice from acute liver injury, providing a mechanistically focused route for compound discovery.

628 records 1/42 page Next 12345 下5页 Last page